EPZ-5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia Research

Executive Summary: EPZ-5676 is a highly selective DOT1L histone methyltransferase inhibitor with an IC₅₀ of 0.8 nM and a Ki of 80 pM, displaying >37,000-fold selectivity over other methyltransferases (APExBIO). It competitively targets the S-adenosyl methionine (SAM) binding pocket of DOT1L, leading to robust H3K79 methylation inhibition and downregulation of MLL-fusion target gene expression (Ishiguro 2025). In vivo studies confirm complete tumor regression in MLL-rearranged leukemia xenograft models at 35–70 mg/kg/day (21 days) without significant toxicity. EPZ-5676 exhibits nanomolar antiproliferative activity in MV4-11 acute leukemia cells and enhances the efficacy of immunomodulatory drugs in preclinical myeloma models. Established protocols and storage guidelines ensure experimental reproducibility and compound stability.

Biological Rationale

DOT1L (disruptor of telomeric silencing 1-like) is a histone methyltransferase responsible for catalyzing the methylation of histone H3 at lysine 79 (H3K79). This mark is associated with transcriptional activation and elongation (Ishiguro 2025). Dysregulation of DOT1L activity is implicated in the pathogenesis of mixed lineage leukemia (MLL)-rearranged leukemias and multiple myeloma. These cancer subtypes exhibit dependency on DOT1L-mediated H3K79 methylation for maintenance of oncogenic gene expression programs (Related analysis). Inhibition of DOT1L leads to downregulation of MLL-fusion target genes, induction of cell cycle arrest, and apoptosis in affected cells. Genome-scale CRISPR studies confirm that DOT1L is an essential epigenetic regulator for survival in these malignancies (Ishiguro 2025).

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ-5676 (also known as pinometostat) is a SAM-competitive inhibitor that binds selectively to the DOT1L active site. It induces a conformational shift that opens a hydrophobic pocket adjacent to the SAM amino acid moiety, blocking substrate methylation (APExBIO). This mechanism results in potent, specific inhibition of H3K79 methylation, with an IC₅₀ of 0.8 nM and a Ki of 80 pM under biochemical assay conditions. Enzyme selectivity screening reveals >37,000-fold specificity compared to CARM1, EHMT1/2, EZH1/2, PRMT family, SETD7, SMYD2/3, and WHSC1/1L1. In MLL-rearranged leukemia cell lines, EPZ-5676 downregulates MLL-fusion gene expression, halts proliferation, and triggers apoptosis. In multiple myeloma, DOT1L inhibition activates interferon-regulated genes and enhances immune signaling, partly via STING pathway activation (Ishiguro 2025).

Evidence & Benchmarks

• EPZ-5676 inhibits DOT1L with an IC₅₀ of 0.8 nM and a Ki of 80 pM in biochemical enzyme assays (APExBIO).
• >37,000-fold selectivity against non-DOT1L methyltransferases, including CARM1, EHMT1/2, EZH1/2, and PRMT family (APExBIO).
• MV4-11 acute leukemia cells (MLL-AF4+) show antiproliferative IC₅₀ of 3.5 nM after 4–7 days; H3K79 methylation is undetectable at 10 nM after 5 days (Site article).
• In vivo, nude rats bearing MV4-11 xenografts treated with 35–70 mg/kg/day for 21 days showed complete tumor regression without significant toxicity (APExBIO).
• DOT1L inhibition in multiple myeloma upregulates interferon-regulated genes, activates STING pathway, and enhances the anti-myeloma effect of lenalidomide (Ishiguro 2025).
• CRISPR/Cas9 knockout of STING1 reduces both IRG induction and anti-proliferative effects of DOT1L inhibitors in MM cells (Ishiguro 2025).
• DOT1L inhibition suppresses IRF4-MYC signaling and ER stress pathway gene transcription, leading to cell cycle arrest and apoptosis in MM models (Ishiguro 2025).

Applications, Limits & Misconceptions

EPZ-5676 is validated for use in biochemical enzyme inhibition assays, cell proliferation studies, and in vivo models of MLL-rearranged leukemia and multiple myeloma. Its selectivity and potency enable precise modulation of H3K79 methylation, making it a reference compound for dissecting epigenetic regulatory mechanisms in cancer. EPZ-5676 also serves as a tool for evaluating combinatorial strategies with immunomodulatory agents (Site article; this article updates the application scope with new in vivo synergy findings).

Common Pitfalls or Misconceptions

• EPZ-5676 is not effective in cancers lacking DOT1L dependency for survival.
• It does not directly inhibit non-MLL-rearranged leukemia subtypes or solid tumors with unrelated epigenetic drivers.
• The compound is insoluble in water and requires DMSO or ethanol (with ultrasonic assistance) for stock solution preparation.
• Long-term storage of solutions above -20°C can reduce compound potency and stability.
• EPZ-5676 is not a general methyltransferase inhibitor; its selectivity profile should guide experimental design (This article clarifies the selectivity boundaries beyond prior reviews).

Workflow Integration & Parameters

EPZ-5676 is supplied as a solid with a molecular weight of 562.71 g/mol. It is soluble at ≥28.15 mg/mL in DMSO and ≥50.3 mg/mL in ethanol (ultrasonic assistance may be required); it is insoluble in water (APExBIO). Stock solutions are stable below -20°C for several months. For cell-based assays (e.g., MV4-11), an IC₅₀ of 3.5 nM is typical after 4–7 days of treatment. In vivo, 35–70 mg/kg/day intravenously for 21 days is an established protocol for tumor regression in xenograft models. Avoid repeated freeze-thaw cycles to maintain compound integrity. The A4166 kit from APExBIO provides standardized quality for research use (DOT1L inhibitor EPZ-5676).

Conclusion & Outlook

EPZ-5676 is a benchmark DOT1L inhibitor, enabling targeted interrogation of H3K79 methylation in MLL-rearranged leukemia and multiple myeloma research. Its specificity and potency underpin translational studies in epigenetic regulation and combinatorial cancer therapy. Ongoing research aims to further delineate its synergy with immunomodulatory agents and to refine its clinical application boundaries. For up-to-date protocols and technical guidance, refer to APExBIO and recent peer-reviewed literature.